Table 1 Descriptive statistics for main analyses (N = 1,884)
From: Long-term prognosis of breast cancer detected by mammography screening or other methods
All age groups | Ages 50 to 69 years | |||||
|---|---|---|---|---|---|---|
Factor | Screening, n(%)a (n= 408) | Outside screening, n(%) (n= 1,476) | Pvalue | Screening, n(%) (n= 347) | Outside screening, n(%) (n= 502) | Pvalue |
Primary tumor diameter (mm) | < 0.001 | < 0.001 | ||||
≤ 10 | 158 (39) | 207 (14) | 143 (41) | 82 (16) | ||
11 to 20 | 179 (44) | 576 (39) | 147 (42) | 204 (41) | ||
21 to 50 | 55 (13) | 581 (39) | 42 (12) | 183 (36) | ||
> 50 | 2 (0) | 66 (4) | 1 (0) | 21 (4) | ||
N.A. | 14 (3) | 46 (3) | 14 (4) | 12 (2) | ||
Nodal status | < 0.001 | < 0.001 | ||||
Negative | 317 (77) | 862 (58) | 273 (79) | 321 (64) | ||
Positive | 85 (21) | 552 (37) | 69 (20) | 178 (35) | ||
N.A. | 6 (1) | 62 (4) | 5 (1) | 3 (0) | ||
Histological type | 0.04 | 0.02 | ||||
Ductal | 287 (70) | 1,104 (75) | 243 (70) | 365 (73) | ||
Lobular | 65 (16) | 232 (16) | 55 (16) | 95 (19) | ||
Special type | 56 (14) | 139 (9) | 49 (14) | 41 (8) | ||
N.A. | 0 | 1 (0) | 0 | 1 (0) | ||
Histological grade | < 0.001 | < 0.001 | ||||
1 | 129 (32) | 241 (16) | 111 (32) | 85 (17) | ||
2 | 147 (36) | 515 (35) | 123 (35) | 172 (34) | ||
3 | 55 (13) | 326 (22) | 43 (12) | 115 (23) | ||
N.A. | 77 (19) | 394 (27) | 70 (20) | 130 (26) | ||
ER content | 0.038 | 0.002 | ||||
Negative | 40 (10) | 232 (16) | 31 (9) | 94 (19) | ||
Positive | 204 (50) | 802 (54) | 172 (50) | 260 (52) | ||
N.A. | 164 (40) | 442 (30) | 144 (41) | 148 (29) | ||
PR content | 0.094 | < 0.001 | ||||
Negative | 79 (19) | 392 (27) | 64 (18) | 171 (34) | ||
Positive | 161 (39) | 620 (42) | 132 (38) | 173 (34) | ||
N.A. | 168 (41) | 464 (31) | 151 (44) | 158 (31) | ||
HER2 | ||||||
Amplification | 0.09 | 0.19 | ||||
Negative | 217 (53) | 852 (58) | 176 (51) | 293 (58) | ||
Positive | 37 (9) | 202 (14) | 32 (9) | 72 (14) | ||
N.A. | 154 (38) | 422 (29) | 139 (40) | 137 (27) | ||
Expression | 0.25 | 0.33 | ||||
Negative | 218 (53) | 889 (60) | 179 (52) | 299 (60) | ||
Positive | 39 (10) | 198 (13) | 33 (10) | 69 (14) | ||
N.A. | 151 (37) | 389 (26) | 135 (39) | 134 (27) | ||
Ki-67 | 0.08 | 0.07 | ||||
Negative | 155 (38) | 615 (42) | 133 (38) | 209 (42) | ||
Positive | 73 (18) | 379 (26) | 54 (16) | 121 (24) | ||
N.A. | 180 (44) | 482 (33) | 160 (46) | 172 (34) | ||
p53 | 0.63 | 0.21 | ||||
Negative | 171 (42) | 786 (53) | 145 (42) | 254 (51) | ||
Positive | 38 (9) | 192 (13) | 31 (9) | 73 (15) | ||
N.A. | 199 (49) | 498 (34) | 171 (49) | 175 (35) | ||
Adjuvant systemic therapy | < 0.001 | < 0.001 | ||||
Not given | 314 (77) | 827 (56) | 271 (78) | 297 (59) | ||
Given | 89 (22) | 609 (41) | 72 (21) | 197 (39) | ||
N.A. | 5 (1) | 40 (3) | 4 (1) | 8 (2) | ||